Dr. Barratt will discuss disease burden and pathogenesis of IgAN, a common cause of kidney failure and a high unmet...
Company’s recent recruitment strategy change has resulted in an unprecedented level of inquiries regarding potential study participationTransplantation of islets into...
VANCOUVER, British Columbia, Nov. 17, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader...
EDIT-101 demonstrates a favorable safety profile across all dose cohorts Preliminary efficacy signals of consistent improvement in BCVA plus additional...
~ Event to be Webcast Live on uniQure’s Corporate Website at 8:30 a.m. EST ~ LEXINGTON, Ma. and AMSTERDAM, Nov....
Survey finds primary care providers wish patients would raise mental health concerns so they can provide better overall careSALT LAKE CITY,...
Lucira Connect – Fast, FREE Covid Care From Home Lucira is the 98% accurate, lab-quality at-home test you can rely...
EMERYVILLE, Calif., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to...
SOUTH SAN FRANCISCO, Calif., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated...
Conformis’ Imprint™ knee system introduces the new “Made-to-Measure” product category option for Total Knee Arthroplasty (TKA)BILLERICA, Mass., Nov. 17, 2022...
SAN FRANCISCO and PHILADELPHIA, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines...
-Broad partnership will strengthen Invivyd’s development platform and organizational capabilities towards acceleration of NVD200 clinical program and future engineered antibodies...
CMR Surgical announces more than 100 Versius systems installed globally CMR is delivering on its commercial strategy of rapid global...
PRESS RELEASE FundaMental Pharma launches with EUR 10 million in Seed financing led by BGV and Thuja Capital to advance...
Interim clinical update on ACTengine® IMA203 TCR-T monotherapy targeting PRAME demonstrated high confirmed objective response rate (cORR) of 50% (6/12)...
- Collaboration will enable the development of investigational next-generation bispecific immunotherapies using CytomX’s Probody® and Regeneron's Veloci-Bi® platforms - -...
BGV co-leads €10 million seed investment in neuroscience company FundaMental Pharma Amsterdam, The Netherlands, 17 November 2022 - BioGeneration Ventures...
MUHC’s Got Talent saw Quebecers vote for their favourite performances by MUHC health care staff, crowning five winners in support...
NEW YORK and BERLIN, Nov. 17, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical...
Up to nine months durability of effect observed in patients aged 55 to 76 in the extension cohort following administration...